AllenLCohnMD

Oncology • Denver, CO

Gastrointestinal Cancer, Genitourinary Oncology, Hematologic Oncology

Medical Oncologist at Rocky Mountain Cancer Centers

Join to view full profile

Dr. Cohn is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Cohn's full profile

Already have an account?

Office
1800 William St
Suite 200
Denver, CO 80218
Phone+1 303-388-4876

Fax+1 303-830-8633
Is this information wrong?

Education & Training

University of Colorado School of MedicineFellowship, Hematology and Medical Oncology, 1991
University of ColoradoResidency, Internal Medicine, 1985 - 1988
University of ColoradoResidency, Internal Medicine, 1986 - 1987
University of ColoradoInternship, Internal Medicine, 1985 - 1986
University of Maryland School of MedicineClass of 1985

Certifications & Licensure

CO State Medical License 1986 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
CORE Magazine Castle Connolly, 2006

Clinical Trials

Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer Start of enrollment: 2005 Sep 01
Completed
Phase 3
A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors Start of enrollment: 2011 Mar 01
Completed
Phase 1
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies Start of enrollment: 2009 Aug 01
Completed
Phase 2
Safety Study of PLX108-01 in Patients With Solid Tumors Start of enrollment: 2009 Oct 01
Completed
Phase 1
Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma Start of enrollment: 2010 Jun 01
Completed
Phase 2
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma Start of enrollment: 2011 Mar 01
Completed
Phase 3
Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer Start of enrollment: 2011 Apr 07
Completed
Phase 2
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Start of enrollment: 2011 Apr 01
Completed
Phase 1, Phase 2
A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer Start of enrollment: 2012 Oct 01
Completed
Phase 1, Phase 2
A Study of BBI503 in Adult Patients With Advanced Solid Tumors Start of enrollment: 2012 Feb 01
Completed
Phase 1
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Start of enrollment: 2013 Aug 01
Completed
Phase 2
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer Start of enrollment: 2013 May 14
Completed
Phase 2
Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) Start of enrollment: 2015 Dec 28
Completed
Phase 3
Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC) Start of enrollment: 2017 Feb 14
Completed
Phase 2
A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors Start of enrollment: 2017 Dec 06
Active, not recruiting
Phase 1, Phase 2
A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) Start of enrollment: 2018 Oct 31
Completed
Phase 2
A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib Start of enrollment: 2019 Feb 08
Active, not recruiting
Phase 3
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) Start of enrollment: 2019 Aug 05
Recruiting
Phase 3
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors Start of enrollment: 2023 Jul 13
Recruiting
Phase 2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomize...
Heinz-Josef Lenz, Aparna Parikh, David R Spigel, Allen L Cohn, Takayuki Yoshino, Mark Kochenderfer, Elena Elez, Spencer H Shao, Dustin Deming, Regan Holdridge, Timothy...> ;Journal for Immunotherapy of Cancer. 2024 Mar 13
1 citations
Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146.
Makker, V., Taylor, M., Aghajanian, C., Cohn, A., Brose, M., Simone, C., Cao, Z., Suttner, L., Loboda, A., Cristescu, R., Jelinic, P., Orlowski, R., Dutta, L., Matsui,...> ;Journal for Immunotherapy of Cancer. 2024 Jan 19
12 citations
Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase ...
Fakih, M., Raghav, K., Chang, D., Larson, T., Cohn, A., Huyck, T., Cosgrove, D., Fiorillo, J., Tam, R., D'Adamo, D., Sharma, N., Brennan, B., Wang, Y., Coppieters, S.,...> ;Eclinicalmedicine. 2023 Apr 1
11 citations
A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update.
Vicky Makker, Carol Aghajanian, Allen L Cohn, Margarita Romeo, Raquel Bratos, Marcia S Brose, Mark Messing, Lea Dutta, Corina E Dutcus, Jie Huang, Emmett V Schmidt, Ro...> ;Journal of Clinical Oncology. 2023 Feb 10
61 citations
Evaluation of cell-free DNA approaches for multi-cancer early detection.
Arash Jamshidi, Minetta C Liu, Eric A Klein, Oliver Venn, Earl Hubbell, John F Beausang, Samuel Gross, Collin Melton, Alexander P Fields, Qinwen Liu, Nan Zhang, Eric T...> ;Cancer Cell. 2022 Dec 12
4 citations
CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burden.
Charles Peterfy, Yan Chen, Peter Countryman, Bartosz Chmielowski, Stephen P Anthony, John H Healey, Zev A Wainberg, Allen L Cohn, Geoffrey I Shapiro, Vicki L Keedy, Ar...> ;Future Oncology. 2022 Apr 1
7 citations
Results from Phase 1 Extension Study Assessing Pexidartinib Treatment in 6 cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT
William D. Tap, Arun S. Singh, Stephen P. Anthony, Mike Sterba, Chao Zhang, John H. Healey, Bartosz Chmielowski, Allen Lee Cohn, Geoffrey I. Shapiro, Vicki L. Keedy, Z...> ;Clinical Cancer Research. 2021 Oct 29
288 citations
Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set.
Eric A. Klein, Donald A. Richards, Allen Lee Cohn, M.K. Tummala, Rosanna Lapham, David Cosgrove, G. Chung, Jessica M. Clement, Jianjun Gao, Nathan Hunkapiller, Arash J...> ;Annals of Oncology. 2021 Sep 1
80 citations
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
Chung-Han Lee, Amishi Yogesh Shah, Drew W. Rasco, Arpit Rao, Matthew H. Taylor, Christopher Di Simone, James J. Hsieh, Alvaro Pinto, David R. Shaffer, Regina Gironés S...> ;The Lancet. Oncology. 2021 Jul 1
18 citations
Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carc...
Thomas Powles, Michael B. Atkins, Bernard Escudier, Robert J. Motzer, Brian I. Rini, Lawrence Fong, Richard W. Joseph, Sumanta K. Pal, Mario Sznol, John D. Hainsworth,...> ;European Urology. 2021 May 1
7 citations
A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer.
Peter Muscarella, Tanios Bekaii-Saab, Kristi McIntyre, Alexander S. Rosemurgy, Sharona Ross, Donald A. Richards, William E. Fisher, Patrick J. Flynn, Alicia Mattson, C...> ;Journal of Pancreatic Cancer. 2021 Mar 23
51 citations
Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF 301 trial
Shalini Makawita, Ghassan K. Abou-Alfa, Sameek Roychowdhury, Saeed Sadeghi, Ivan Borbath, Lipika Goyal, Allen Cohn, Angela Lamarca, Do Youn Oh, Teresa Macarulla, Rachn...> ;Future Oncology. 2020 Jun 25
291 citations
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
Vicky Makker, Matthew H. Taylor, Carol Aghajanian, Ana Oaknin, James W. Mier, Allen Lee Cohn, Margarita Romeo, Raquel Bratos, Marcia S. Brose, Christopher DiSimone, Ma...> ;Journal of Clinical Oncology. 2020 Mar 13
8 citations
Corrigendum: Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: A randomized, double...
Harry H. Yoon, Johanna C. Bendell, Fadi Braiteh, Irfan Firdaus, Philip A. Philip, Allen Lee Cohn, Nancy L. Lewis, Edward Arrowsmith, Jonathan D. Schwartz, Ling Gao, Ya...> ;Annals of Oncology. 2019 Dec 1
320 citations
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
Vicky Makker, Drew W. Rasco, Nicholas J. Vogelzang, Marcia S. Brose, Allen Lee Cohn, James W. Mier, Christopher Di Simone, David M. Hyman, Daniel E. Stepan, Corina E. ...> ;The Lancet. Oncology. 2019 May 1
14 citations
Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018).
Sneha Berry, Nicolas A. Giraldo, Peter Nguyen, Benjamin Green, Haiying Xu, Aleksandra Ogurtsova, Abha Soni, Farah Succaria, Daphne Wang, Charles Roberts, Julie E. Stei...> ;Journal for Immunotherapy of Cancer. 2019 Feb 13
44 citations
Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinom...
Takayuki Yoshino, David Craig Portnoy, Radka Obermannova, G. Bodoky, Jana Prausová, Rocio Garcia-Carbonero, Tudor-Eliade Ciuleanu, P. García-Alfonso, Allen Lee Cohn, E...> ;Annals of Oncology. 2019 Jan 1
23 citations
Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.
David R. Fogelman, Antonio Cubillo, Pilar García-Alfonso, Maria Luisa Limon Miron, John Nemunaitis, Daniel Blake Flora, Christophe Borg, Laurent Mineur, Jose María Vie...> ;Cancer Medicine. 2018 Nov 1
19 citations
Multicenter, randomized, double‐blind phase 2 trial of FOLFIRI with regorafenib or placebo as second‐line therapy for metastatic colorectal cancer
Hanna K. Sanoff, Richard M. Goldberg, Anastasia Ivanova, Seamus O'Reilly, Samer S. Kasbari, Richard D. Kim, Ray McDermott, Dominic T. Moore, William C. Zamboni, Willia...> ;Cancer. 2018 Aug 1
1498 citations
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;The Lancet. Oncology. 2018 Jul 1
20 citations
Whole Recombinant Saccharomyces cerevisiae Yeast Expressing Ras Mutations as Treatment for Patients With Solid Tumors Bearing Ras Mutations: Results From a Phase 1 Trial.
Allen Lee Cohn, Michael A. Morse, Bert H. O'Neil, Samuel Whiting, Claire Coeshott, John Ferraro, Donald Bellgrau, David Apelian, Timothy C. Rodell> ;Journal of Immunotherapy. 2018 Apr 1
41 citations
A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma.
Martin H. Voss, Arif Hussain, Nicholas J. Vogelzang, J.-L. Lee, Bhumsuk Keam, Sun Young Rha, Ulka N. Vaishampayan, W. B. Harris, Stephen Lane Richey, J. M. Randall, Da...> ;Annals of Oncology. 2017 Nov 1
74 citations
Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III st...
Josep Tabernero, Rebecca R. Hozak, Takayuki Yoshino, Allen Lee Cohn, Radka Obermannova, G. Bodoky, Rocio Garcia-Carbonero, Tudor-Eliade Ciuleanu, David Craig Portnoy, ...> ;Annals of Oncology. 2017 Sep 1
17 citations
Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial.
Allen Lee Cohn, Takayuki Yoshino, Volker Heinemann, Radka Obermannova, György Bodoky, Jana Prausová, Rocio Garcia-Carbonero, Tudor Ciuleanu, Pilar García-Alfonso, Davi...> ;Cancer Chemotherapy and Pharmacology. 2017 Jul 25
16 citations
Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: Observations from a US regional analysis of the GIDEON registry
Robert C.G. Martin, Elizabeth H. Bruenderman, Allen Lee Cohn, Bilal Piperdi, Rebecca A. Miksad, Jean Francois H. Geschwind, Alec Goldenberg, Arun J. Sanyal, Ellen Zigm...> ;American Journal of Surgery. 2017 Apr 1
Join now to see all

Lectures

The Circulating Cell-free Genome Atlas (CCGA) Study: Follow-up (F/U) on non-cancer participants with cancer-like cell-free DNA signals.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Photographer, Cancer Survivor Gives Presentation in Steamboat on Year Spent Shooting from His Car WindowSeptember 17th, 2019
Increased Incidence Drives Novel Approaches Across Pancreatic Cancer SettingsJune 27th, 2019
Rocky Mountain Cancer Centers First in Region to Offer Newly Approved Gallium DOTATATE PET/CT for Neuroendocrine TumorsNovember 15th, 2016